6 results on '"Orianne, Lacroix"'
Number of results to display per page
Search Results
2. Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys
- Author
-
Mathieu Mateo, Jimmy Hortion, Emeline Perthame, Caroline Picard, Stéphanie Reynard, Alexandra Journeaux, Clara Germain, Xavier Carnec, Nicolas Baillet, Virginie Borges-Cardoso, Natalia Pietrosemoli, Audrey Vallve, Stéphane Barron, Ophélie Jourjon, Orianne Lacroix, Aurélie Duthey, Manon Dirheimer, Maïlys Daniau, Catherine Legras-Lachuer, Gregory Jouvion, Caroline Carbonnelle, Hervé Raoul, and Sylvain Baize
- Subjects
Lassa virus ,cynomolgus monkeys ,pathogenesis ,immune responses ,viral hemorrhagic fevers ,Infectious and parasitic diseases ,RC109-216 - Abstract
The area of Lassa virus (LASV) circulation is expanding, with the emergence of highly pathogenic new LASV lineages. Benin recently became an endemic country for LASV and has seen the emergence of a new LASV lineage (VII). The first two outbreaks in 2014 and 2016 showed a relatively high mortality rate compared to other outbreaks. We infected cynomolgus monkeys with two strains belonging to lineage II and lineage VII that were isolated from deceased patients during the 2016 outbreak in Benin. The lineage VII strain (L7) caused uniform mortality. Death was associated with uncontrolled viral replication, unbalanced inflammatory responses characterized by increased concentrations of pro- and anti-inflammatory mediators, and the absence of efficient immune responses, resembling the pathogenesis associated with the prototypic Josiah strain in monkeys. The lineage II strain (L2) showed apparently lower virulence than its counterpart, with a prolonged time to death and a lower mortality rate. Prolonged survival was associated with better control of viral replication, a moderate inflammatory response, and efficient T-cell responses. Transcriptomic analyses also highlighted important differences in the immune responses associated with the outcome. Both strains caused strong inflammation in several organs. Notably, meningitis and encephalitis were observed in the cerebral cortex and cerebellum in all monkeys, independently of the outcome. Due to their apparently high pathogenicity, emerging strains from lineage VII should be considered in preclinical vaccine testing. Lineage II would also be beneficial in pathogenesis studies to study the entire spectrum of Lassa fever severity.
- Published
- 2022
- Full Text
- View/download PDF
3. Natural History of Sudan ebolavirus to Support Medical Countermeasure Development
- Author
-
Caroline Carbonnelle, Marie Moroso, Delphine Pannetier, Sabine Godard, Stéphane Mély, Damien Thomas, Aurélie Duthey, Ophélie Jourjon, Orianne Lacroix, Béatrice Labrosse, Hervé Raoul, Karen L. Osman, Francisco J. Salguero, Yper Hall, Carol L. Sabourin, Michael J. Merchlinsky, James P. Long, Lindsay A. Parish, and Daniel N. Wolfe
- Subjects
Sudan ebolavirus ,SUDV ,Ebola ,natural history study ,filovirus ,macaques ,Medicine - Abstract
Sudan ebolavirus (SUDV) is one of four members of the Ebolavirus genus known to cause Ebola Virus Disease (EVD) in humans, which is characterized by hemorrhagic fever and a high case fatality rate. While licensed therapeutics and vaccines are available in limited number to treat infections of Zaire ebolavirus, there are currently no effective licensed vaccines or therapeutics for SUDV. A well-characterized animal model of this disease is needed for the further development and testing of vaccines and therapeutics. In this study, twelve cynomolgus macaques (Macaca fascicularis) were challenged intramuscularly with 1000 PFUs of SUDV and were followed under continuous telemetric surveillance. Clinical observations, body weights, temperature, viremia, hematology, clinical chemistry, and coagulation were analyzed at timepoints throughout the study. Death from SUDV disease occurred between five and ten days after challenge at the point that each animal met the criteria for euthanasia. All animals were observed to exhibit clinical signs and lesions similar to those observed in human cases which included: viremia, fever, dehydration, reduced physical activity, macular skin rash, systemic inflammation, coagulopathy, lymphoid depletion, renal tubular necrosis, hepatocellular degeneration and necrosis. The results from this study will facilitate the future preclinical development and evaluation of vaccines and therapeutics for SUDV.
- Published
- 2022
- Full Text
- View/download PDF
4. A MOPEVAC multivalent vaccine induces sterile protection against New World arenaviruses in non-human primates
- Author
-
Stéphanie Reynard, Xavier Carnec, Caroline Picard, Virginie Borges-Cardoso, Alexandra Journeaux, Mathieu Mateo, Clara Germain, Jimmy Hortion, Laure Albrecht, Emeline Perthame, Natalia Pietrosemoli, Audrey Vallvé, Stéphane Barron, Aurélie Duthey, Orianne Lacroix, Ophélie Jourjon, Marie Moroso, Lyne Fellmann, Pierre-Henri Moreau, Maïlys Daniau, Catherine Legras-Lachuer, Manon Dirheimer, Caroline Carbonnelle, Hervé Raoul, Sylvain Baize, Biologie des Infections Virales Émergentes - Biology of Emerging Viral Infections (UBIVE), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hub Bioinformatique et Biostatistique - Bioinformatics and Biostatistics HUB, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Laboratoire P4 - Jean Mérieux, Centre Européen de Virologie/Immunologie-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Strasbourg (UNISTRA), ViroScan3D SAS [Trévoux, France], Délégation régionale Auvergne Rhône-Alpes [Bron, France], and Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Microbiology (medical) ,Antibodies Neutralizing ,Arenaviruses New World ,[SDV]Life Sciences [q-bio] ,Immunology ,Vaccines Combined ,Cell Biology ,Applied Microbiology and Biotechnology ,Microbiology ,Macaca fascicularis ,Genetics ,Animals ,[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology ,Glycoproteins - Abstract
International audience; Pathogenic New World arenaviruses (NWAs) cause haemorrhagic fevers and can have high mortality rates, as shown in outbreaks in South America. Neutralizing antibodies (Abs) are critical for protection from NWAs. Having shown that the MOPEVAC vaccine, based on a hyperattenuated arenavirus, induces neutralizing Abs against Lassa fever, we hypothesized that expression of NWA glycoproteins in this platform might protect against NWAs. Cynomolgus monkeys immunized with MOPEVACMAC, targeting Machupo virus, prevented the lethality of this virus and induced partially NWA cross-reactive neutralizing Abs. We then developed the pentavalent MOPEVACNEW vaccine, expressing glycoproteins from all pathogenic South American NWAs. Immunization of cynomolgus monkeys with MOPEVACNEW induced neutralizing Abs against five NWAs, strong innate followed by adaptive immune responses as detected by transcriptomics and provided sterile protection against Machupo virus and the genetically distant Guanarito virus. MOPEVACNEW may thus be efficient to protect against existing and potentially emerging NWAs.
- Published
- 2023
- Full Text
- View/download PDF
5. Natural History of
- Author
-
Caroline, Carbonnelle, Marie, Moroso, Delphine, Pannetier, Sabine, Godard, Stéphane, Mély, Damien, Thomas, Aurélie, Duthey, Ophélie, Jourjon, Orianne, Lacroix, Béatrice, Labrosse, Hervé, Raoul, Karen L, Osman, Francisco J, Salguero, Yper, Hall, Carol L, Sabourin, Michael J, Merchlinsky, James P, Long, Lindsay A, Parish, and Daniel N, Wolfe
- Published
- 2022
6. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains
- Author
-
P. Moreau, Ophélie Jourjon, Virginie Borges-Cardoso, Caroline Picard, Manon Dirheimer, Xavier Carnec, Lyne Fellmann, Othmann Merabet, Clara Germain, Mathieu Mateo, Aurélie Duthey, Stéphanie Reynard, Alexandra Journeaux, Hervé Raoul, Jimmy Hortion, Frédéric Tangy, Gregory Jouvion, Audrey Vallve, Stéphane Barron, Caroline Carbonnelle, Nicolas Baillet, Orianne Lacroix, Sylvain Baize, Biologie des Infections Virales Émergentes - Biology of Emerging Viral Infections (UBIVE), Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris] (IP), Laboratoire P4 - Jean Mérieux, Centre Européen de Virologie/Immunologie-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM), École nationale vétérinaire - Alfort (ENVA), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Université de Strasbourg (UNISTRA), Génomique Virale et Vaccination, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), This study was entirely funded by a grant from the Coalition for Epidemic Preparedness and Innovations (CEPI-CfP-001) to S. Baize, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], École nationale vétérinaire d'Alfort (ENVA), Baize, Sylvain, and Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris] (IP)
- Subjects
0301 basic medicine ,viruses ,Heterologous ,medicine.disease_cause ,Measles virus ,03 medical and health sciences ,[SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology ,Lassa Fever ,0302 clinical medicine ,Immune system ,medicine ,Animals ,030212 general & internal medicine ,Vector (molecular biology) ,Lassa virus ,biology ,virus diseases ,Outbreak ,Viral Vaccines ,General Medicine ,Vaccine efficacy ,biology.organism_classification ,Virology ,3. Good health ,Nucleoprotein ,Africa, Western ,Macaca fascicularis ,Nucleoproteins ,030104 developmental biology ,[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology - Abstract
Acknowledgments: We thank P. Regnard (Silabe, Strasbourg) for medical care given to the monkeys. We thank S. Mundweiller, S. Godard, E. Moissonnier, D. Thomas, S. Mély, B. Labrosse, D. Pannetier, and C. Léculier (P4 INSERM–Jean Mérieux, US003, INSERM) for assistance in conducting the BSL-4 experiments. We are grateful to G. Fourcaud and B. Lafoux (Institut Pasteur, CIRI, Lyon) for technical help with histological studies. We thank S. Becker for providing us with the Josiah strain and T. G. Ksiasek, P. E. Rollin, and P. Jahrling for the LASV monoclonal antibodies. We also thank L. Branco (Zalgen Labs) for providing recombinant proteins. We are grateful to THEMIS Bioscience GmbH, a wholly owned subsidiary of Merck & Co. Inc. (E. Tauber, A. Kort, K. Ramsauer, S. Schrauf, Y. Tomberger, and R. Tschismarov), to the Coalition for Epidemic Preparedness and Innovations (R. Hatchett, G. Thiry, and M. Saville), and to C. Gerke (Department of Innovation Development, Institut Pasteur) for invaluable support; International audience; A safe and protective Lassa virus vaccine is crucially needed in Western Africa to stem the recurrent outbreaks of Lassa virus infections in Nigeria and the emergence of Lassa virus in previously unaffected countries, such as Benin and Togo. Major challenges in developing a Lassa virus vaccine include the high diversity of circulating strains and their reemergence from 1 year to another. To address each of these challenges, we immunized cynomolgus monkeys with a measles virus vector expressing the Lassa virus glycoprotein and nucleoprotein of the prototypic Lassa virus strain Josiah (MeV-NP). To evaluate vaccine efficacy against heterologous strains of Lassa virus, we challenged the monkeys a month later with heterologous strains from lineage II or lineage VII, finding that the vaccine was protective against these strains. A second cohort of monkeys was challenged 1 year later with the homologous Josiah strain, finding that a single dose of MeV-NP was sufficient to protect all vaccinated monkeys. These studies demonstrate that MeV-NP can generate both long-lasting immune responses and responses that are able to protect against diverse strains of Lassa virus.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.